Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160265 | 1.00 | THRB (0.40) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL387178 | 1.00 | THRB (0.40) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| Glycolic Acid SCHEMBL28099037 | 0.90 | FFAR3 (0.35) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| Glycine SCHEMBL29869337 | 0.88 | GLRA1 (0.46) | THRBSLC1A3SLC1A2SLC1A1MMP1 | |
| SCHEMBL26940409 | 0.87 | MMP1 (0.48) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL9628984 | 0.87 | MMP1 (0.48) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL7069046 | 0.85 | LMNA (0.38) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL2963336 | 0.85 | TSHR (0.41) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL11382908 | 0.83 | TDP1 (0.36) | THRBSLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL2985403 | 0.83 | MMP1 (0.32) | THRBSLC1A3SLC1A2SLC1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010284-A1 | DUAL METAL CYANIDE CATALYST, PREPARATION METHOD THEREFOR, AND METHOD FOR PREPARING POLYCARBONATE POLYOL BY USING CATALYST | POSCO CO., LTD (KR) | 2019-01-10 | — | — | US | claimed |
| EP-1802584-B1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SULFOXIDES | RANBAXY LAB LTD (IN) | 2009-09-16 | — | — | EP | claimed |
| EP-1539768-A2 | A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE METHODS OF PREPARING SAME | Novartis AG (CH) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024735-A2 | A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE METHODS OF PREPARING SAME | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | claimed |
| EP-0693704-B1 | Semi-organic crystals for nonlinear optical devices | ROCKWELL INTERNATIONAL CORP (US) | 2002-08-28 | — | — | EP | claimed |
| EP-0772646-B1 | FLUOROELASTOMER MOULDING PROCESS | DU PONT (US) | 2000-03-01 | — | — | EP | claimed |
| EP-0772646-A4 | FLUOROELASTOMER MOULDING PROCESS | DU PONT (US) | 1997-12-10 | — | — | EP | claimed |
| EP-0772646-A1 | FLUOROELASTOMER MOULDING PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996001870-A1 | FLUOROELASTOMER MOULDING PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-25 | — | — | WO | claimed |
| EP-0693704-A1 | Semi-organic crystals for nonlinear optical devices | ROCKWELL INTERNATIONAL CORPORATION (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0691371-A1 | Fluoroelastomer compositions | DU PONT DE NEMOURS INTERNATIONAL S.A. (CH) | 1996-01-10 | — | — | EP | claimed |
| EP-0255379-B1 | Optically active alcohols, process for producing the same, and process for resolving the same | NISSAN CHEMICAL IND LTD (JP) | 1995-11-15 | — | — | EP | claimed |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10619006-B2 | Dual metal cyanide catalyst, preparation method therefor, and method for preparing polycarbonate polyol by using catalyst | POSCO (KR) | 2020-04-14 | — | — | US | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-0241235-A2 | Process for the preparation of homoallyl alcohols | ICI AUSTRALIA LIMITED (AU) | 1987-10-14 | — | — | EP | disclosed |
| US-4668814-A | ANTIULCER AGENTS, ANTIASHMATICS, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4552695-A | Process for production of diltiazem hydrochloride | SHIONOGI & CO., LTD. (JP) | 1985-11-12 | — | — | US | disclosed |
| EP-0159784-A1 | Carbacyclin analogues | THE UPJOHN COMPANY (US) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | THRB 3471/4885SLC1A3 1693/4885SLC1A2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.